赛尔群（068270.KS）股价与投研分析
Celltrion · 韩国市场 · 医药健康
关键指标
- 最新价
- KRW 206500.00
- 日内涨跌
- -3.95%
- 市值
- KRW 47.09 万亿
- 市盈率 TTM
- —
- 市净率
- —
- 52 周最高
- KRW 239047.62
- 52 周最低
- KRW 158500.00
- 股息率
- 36.00%
- 成交量
- 股 13.15 万
- 上市市场
- 韩国
公司概况
赛尔群（英文名 Celltrion，股票代码 068270.KS）在韩国市场上市， 属于医药健康行业，当前处于成长阶段。核心标签：生物仿制药、生物药。
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
AI 三层投研框架
- 宏观周期层：利率、通胀、汇率与流动性如何影响韩国市场的估值中枢。
- 行业格局层：用 PEST、波特五力与产业链位置判断医药健康行业的利润分配。
- 公司质地层：把 赛尔群 的增速、利润率、ROE 与现金流放进同行业横向对比。
需要完整报告？回到终端 可基于真实财报数据生成三层 AI 分析。